Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 80,000 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 80,000 shares of Natera stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $90.82, for a total transaction of $7,265,600.00. Following the sale, the insider now directly owns 117,560 shares in the company, valued at approximately $10,676,799.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Natera Price Performance

NASDAQ NTRA opened at $90.33 on Thursday. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The company has a 50-day simple moving average of $85.39 and a 200-day simple moving average of $65.41. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Equities analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several analyst reports. BTIG Research lifted their price target on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Craig Hallum initiated coverage on shares of Natera in a research report on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research report on Friday, April 5th. Finally, Canaccord Genuity Group boosted their target price on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. RiverPark Advisors LLC acquired a new position in Natera during the 4th quarter valued at about $27,000. Principal Securities Inc. acquired a new position in Natera during the 4th quarter valued at about $32,000. Oliver Lagore Vanvalin Investment Group boosted its stake in Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the period. Harvest Fund Management Co. Ltd acquired a new stake in shares of Natera in the 3rd quarter worth approximately $44,000. Finally, CWM LLC lifted its stake in shares of Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after acquiring an additional 911 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.